Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Single-dose pharmacokinetics of the HCV polymerase inhibitor mericitabine in healthy Caucasian and Japanese subjects.

Washington C, Moreira S, Haznedar J, Goelzer P, Chen YC.

Drug Metab Pharmacokinet. 2014;29(2):141-7. Epub 2013 Sep 10.

2.

The effect of mild to moderate renal impairment on the pharmacokinetics of the nucleoside analog hepatitis C virus polymerase inhibitor mericitabine.

Haznedar J, Moreira S, Marbury T, Robson R, Smith W, Kulkarni R, Munson ML, Thommes JA, Lemenuel-Diot A, Washington C, Smith P, Chen YC.

Drug Dev Res. 2014 Mar;75(2):107-13. doi: 10.1002/ddr.21166. Epub 2013 Dec 26.

PMID:
24648253
3.

Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects.

Hara K, Takahashi N, Wakamatsu A, Caltabiano S.

Drug Metab Pharmacokinet. 2015 Dec;30(6):410-8. doi: 10.1016/j.dmpk.2015.08.004. Epub 2015 Aug 28.

PMID:
26643993
4.

Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects.

Zannikos P, Novak G, Yao C, Verhaeghe T, Franc MA, Solanki B, Bialer M.

Epilepsia. 2009 Aug;50(8):1850-9. doi: 10.1111/j.1528-1167.2009.02081.x. Epub 2009 May 11.

5.

Evaluation of the effect of mericitabine at projected therapeutic and supratherapeutic doses on cardiac repolarization in healthy subjects: A thorough QT/QTc study.

Chen YC, Haznedar J, Kulkarni R, Vistuer C, Washington C, Liu M, Smith P.

Clin Pharmacol Drug Dev. 2014 May;3(3):179-86. doi: 10.1002/cpdd.79. Epub 2014 Feb 6.

PMID:
27128607
6.

Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects.

Schentag JJ, Hill G, Chu T, Rayner CR.

J Clin Pharmacol. 2007 Jun;47(6):689-96. Epub 2007 Apr 24.

PMID:
17456583
7.

Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects.

Zhao Q, Brett M, Van Osselaer N, Huang F, Raoult A, Van Peer A, Verhaeghe T, Hust R.

J Clin Pharmacol. 2002 Sep;42(9):1002-10.

PMID:
12211216
8.

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.

Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.

Clin Ther. 2010 Jun;32(6):1188-204. doi: 10.1016/j.clinthera.2010.06.004.

PMID:
20637971
9.

Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteers.

Sun Y, He X, Qiu F, Zhu X, Zhao M, Li-Ling J, Su X, Zhao L.

Int J Clin Pharmacol Ther. 2013 May;51(5):423-32. doi: 10.5414/CP201843.

PMID:
23391367
10.

Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers.

Teng R, Butler K.

Int J Clin Pharmacol Ther. 2014 Jun;52(6):478-91. doi: 10.5414/CP202017.

PMID:
24755129
11.
12.

Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.

Reigner B, Watanabe T, Schüller J, Lucraft H, Sasaki Y, Bridgewater J, Saeki T, McAleer J, Kuranami M, Poole C, Kimura M, Monkhouse J, Yorulmaz C, Weidekamm E, Grange S.

Cancer Chemother Pharmacol. 2003 Sep;52(3):193-201. Epub 2003 May 29.

PMID:
12783206
13.

The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males.

Shida Y, Hara K, Nohda S, Soutome T, Hirama T.

J Clin Pharm Ther. 2013 Jun;38(3):236-40. doi: 10.1111/jcpt.12056. Epub 2013 Mar 14.

PMID:
23489210
14.

Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects.

Thomsen MS, Chassard D, Evène E, Nielsen KK, Jørgensen M.

J Clin Pharmacol. 2003 Jan;43(1):23-8.

PMID:
12520624
15.
16.

Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity.

Chen N, Kasserra C, Reyes J, Liu L, Lau H.

Cancer Chemother Pharmacol. 2012 Nov;70(5):717-25. doi: 10.1007/s00280-012-1966-z. Epub 2012 Sep 6.

PMID:
22955172
17.

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

Horie Y, Kanada S, Watada H, Sarashina A, Taniguchi A, Hayashi N, Graefe-Mody EU, Woerle HJ, Dugi KA.

Clin Ther. 2011 Jul;33(7):973-89. doi: 10.1016/j.clinthera.2011.06.005. Epub 2011 Jul 2.

PMID:
21723606
18.

Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.

Mück W, Unger S, Kawano K, Ahr G.

Br J Clin Pharmacol. 1998 Jun;45(6):583-90.

19.

Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.

Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M.

Clin Ther. 2012 Oct;34(10):2144-60. doi: 10.1016/j.clinthera.2012.09.010.

PMID:
23063375
20.

Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.

Cheng YF, Jiang J, Hu P, Reinholdsson I, Guo W, Asenblad N, Nilsson D.

Clin Ther. 2008 Dec;30(12):2342-53. doi: 10.1016/j.clinthera.2008.12.013.

PMID:
19167593

Supplemental Content

Support Center